The favorable results from the placebo-controlled FLOW trial, conducted with semaglutide 1.0 mg in patients with T2D and chronic kidney disesase (CKD), are about to be disclosed, while ongoing dedicated trials will further explore the effects of OW semaglutide 2.4 mg (NCT04889183) and tirzepatide (NCT05536804) on kidney function parameters in obese/overweight individuals at high risk of CKD progression regardless of T2D
When you inject too early, you amplify this effect
However, individual responses vary, and the medication does not specifically eliminate cravings for sweet foods
The purchaser assumes full responsibility for handling, use, and regulatory compliance.
OH BABY IM DOWN 52lbs I love sharing my weight-loss journey with yall because truthfully, Ive been so hard on myself behind the scenes, she captioned her post on May 5, 2025, which included side-by-side images of how she looked before losing the weight and now
Monitor for excessive gastrointestinal distress (nausea, vomiting, diarrhoea), significant mood changes or anxiety, unusual fatigue, sleep disturbances, and signs of dehydration